(Q34232014)

31 July 2017

title

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. (English)

1 reference

31 July 2017

0 references

therapeutic indication

1 reference

Paranjape SB

1

1 reference

31 July 2017

Thibonnier M

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

825-834

1 reference

Baroreceptor influences on oxytocin and vasopressin secretion

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Signal transduction of V1-vascular vasopressin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Cytoplasmic and nuclear signaling pathways of V1-vascular vasopressin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Molecular cloning of the receptor for human antidiuretic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Cloning and characterization of the human V3 pituitary vasopressin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Anomalous antidiuretic activity of antidiuretic hormone antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Evidence against a pressor role for vasopressin in spontaneous hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.825

10.1517/13543784.10.5.825

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ekqrve5bbbf23cmitma66gad7u

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_ekqrve5bbbf23cmitma66gad7u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ekqrve5bbbf23cmitma66gad7u

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/ekqrve5bbbf23cmitma66gad7u

1 reference